-
1 Comment
Ipca Laboratories Limited is currently in a long term uptrend where the price is trading 1.6% above its 200 day moving average.
From a valuation standpoint, the stock is 6.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Ipca Laboratories Limited's total revenue rose by 16.2% to $14B since the same quarter in the previous year.
Its net income has increased by 34.3% to $3B since the same quarter in the previous year.
Finally, its free cash flow fell by 0.0% to $4B since the same quarter in the previous year.
Based on the above factors, Ipca Laboratories Limited gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Industry | Drug Manufacturers - Specialty & Generic |
Exchange | NSE |
CurrencyCode | INR |
ISIN | INE571A01038 |
Dividend Yield | 0.0% |
---|---|
Beta | 0.16 |
PE Ratio | 44.49 |
Market Cap | 347B |
Target Price | 1507.2941 |
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IPCALAB.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025